EIB agrees €75m financing for Germany's CureVac
The European Investment Bank has signed a €75 million loan agreement with Germany-based CureVac, a clinical-stage biopharmaceutical company.
The financing will support the company’s ongoing development of vaccines against infectious diseases, including its vaccine candidate CVnCoV aimed at preventing SARS-CoV-2 infections.
In addition, the loan will support CureVac's efforts to expand its existing Good Manufacturing Practice certified production capabilities and accelerate the completion of its fourth production site in Tubingen, Germany. The EIB financing will be provided in three €25 million tranches upon completion of pre-defined milestones.